Rytelo savings card: as little as $0 an infusion with commercial insurance

Rytelo is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Rytelo is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameRytelo

Authorized genericimetelstat

Regular genericimetelstat

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Rytelo?

The original

–

Brand nameThe maker’s card

REACH4RYTELO Copay Program

Savings card from Geron Corporation

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 an infusion

The card takes up to $9,450 a year off your co-pay.

Or call 1-844-479-8356.

In the maker’s words

“If eligible for the Copay Program, the patient may pay as little as $0 out-of-pocket for RYTELO with a maximum benefit of $9450 per year for the cost of the drug and a maximum benefit of $1200 per year for the cost of administration (up to $100 per infusion).”

From the maker’s offer on rytelo.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Rytelo itself, from the same company, sold without the brand name, and usually for less. For now Rytelo is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Myelodysplastic syndromes (MDS) needing blood transfusions

What the FDA label says

RYTELO is an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).

Source: the FDA label for Rytelo (Geron Corporation), April 22, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/rytelo/